<DOC>
	<DOC>NCT01459809</DOC>
	<brief_summary>Primary Objective: - To demonstrate the superiority of glimepiride and metformin free combination in comparison to glimepiride or metformin alone in terms of Hb1Ac reduction during a 24-week treatment period in patients with type 2 diabetes mellitus. Secondary Objectives: - To assess the effects of the free combination of glimepiride and metformin in comparison to glimepiride or metformin alone on: - Percentage of patients reaching HbA1c &lt; 7% - Percentage of patients reaching HbA1c &lt; 6.5% - Fasting Plasma Glucose (FPG) - Safety and tolerability</brief_summary>
	<brief_title>Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients</brief_title>
	<detailed_description>The study duration for each patient is approximately 27 weeks with 3 periods: 2-week screening period followed by 24-week treatment period where patient is assigned to one of the three arms according to randomization, and 3 days follow-up period with a last call phone visit.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria Patients with type 2 diabetes mellitus, as defined by the World Health Organization (WHO), diagnosed within one year prior to the screening visit Signed informed consent, obtained prior to any study procedure Exclusion criteria Age &lt; 18 and =&gt; 78 years old HbA1c &lt; 7.6% or &gt; 9% BMI &gt; 35 kg/m2 Diabetes other than type 2 diabetes (e.g.: type 1 diabetes, diabetes secondary to pancreatic disorders, drug or chemical agent intake...) Subjects currently receiving or who have received any hypoglycemic agent within 3 months before screening visit The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>